Convergent Therapeutics, Inc.

📍 Cambridge, United States🗓 Founded 2021👥 20 employees💰 Last funded Nov 2024
Biotechnology Research🌐 convergentrx.com
Website LinkedIn
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Convergent Therapeutics, Inc.?
Convergent Therapeutics, Inc. has 1 investors on record on gritt.io, 1 mid-stage.
When did Convergent Therapeutics, Inc. last raise funding?
The most recent investment in Convergent Therapeutics, Inc. recorded on gritt.io was in November 2024.
When was Convergent Therapeutics, Inc. founded?
Convergent Therapeutics, Inc. was founded in 2021.
What industry is Convergent Therapeutics, Inc. in?
Convergent Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Convergent Therapeutics, Inc. based?
Convergent Therapeutics, Inc. is headquartered in Cambridge, United States.